Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Atiye Cenay Karabörk Kılıç"'
Autor:
Volkan Aslan, Atiye Cenay Karabörk Kılıç, Ahmet Özet, Aytuğ Üner, Nazan Günel, Ozan Yazıcı, Gözde Savaş, Ahmet Bayrak, Emrah Eraslan, Berna Öksüzoğlu, Hüseyin Koray Kılıç, Nuriye Özdemir
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Introduction Resistance to immune checkpoint inhibitors (ICI) is a significant issue in metastatic renal cell carcinoma (mRCC), as it is in the majority of cancer types. An important deficiency in immunooncology today is the lack of a predic
Externí odkaz:
https://doaj.org/article/064c7efbc4eb4b068e1b246c055dc512
Autor:
Halit Nahit Şendur, Mahi N. Cerit, Turkana Fatullayeva, Zeynep S. Erdal, Atiye Cenay Karabörk Kılıç, Suna Özhan Oktar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::513e43a9edd8033e5824d788dae43597
https://avesis.gazi.edu.tr/publication/details/3a903c19-5710-4547-b776-22e33eff5fc2/oai
https://avesis.gazi.edu.tr/publication/details/3a903c19-5710-4547-b776-22e33eff5fc2/oai
Autor:
Volkan Aslan, Atiye Cenay Karabörk Kılıç, Osman Sütcüoğlu, Emrah Eraslan, Ahmet Bayrak, Berna Öksüzoğlu, Gözde Tahtacı, Nuriye Özdemir, Aytuğ Üner, Nazan Günel, Ahmet Özet, Ozan Yazıcı
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 40:494.e1-494.e10
Immune checkpoint inhibitors (ICI) have transformed treatments for patients with metastatic renal cell carcinoma (mRCC). Although some patients benefit greatly from ICI treatments, an effective marker to determine which patients will benefit from the